- Home
- BCG vs JSPR Comparison
BCG vs JSPR Comparison
Compare BCG & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCG | JSPR |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | United States |
| Employees | N/A | 64 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.8M | 34.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BCG | JSPR |
|---|---|---|
| Price | $2.39 | $0.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | ★ 704.6K | 371.6K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $56.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.36 | $0.69 |
| 52 Week High | $3.44 | $7.19 |
Technical Indicators
Market Signals| Indicator | BCG | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 57.48 | 16.03 |
| Support Level | $1.94 | N/A |
| Resistance Level | $2.53 | $1.44 |
| Average True Range (ATR) | 0.17 | 0.09 |
| MACD | 0.04 | -0.05 |
| Stochastic Oscillator | 29.66 | 1.60 |
Price Performance
Historical ComparisonAbout BCG Binah Capital Group Inc.
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.